The nasal-spray Covid-19 vaccine “NASTVAC” : COVID-19 Intranasal Vaccines developed by Thailand’s National Centre for Genetic Engineering and Biotechnology (Biotech)-NSTDA, is expected to start testing on humans by April 2022. The PI of this project is Dr. Anan Jongkaewwattana Dr Anan Jongkaewwattana, director of the agency’s Veterinary Health Innovation and Management Research Group Unit.
It is with great pleasure of Bangkok R.I.A. group to support NASTVAC, COVID-19 Intranasal Vaccines research project for Thai people. We are hopeful and proud of NSTDA – Biotech team that strengthen Thailand’s capacity in producing COVID-19 Intranasal Vaccines from upstream to downstream. The importance of supporting research and development of locally-made vaccines will help our country get through this difficult time and return back to normal.
